Insulin syringe market seen reaching $3 billion by 2035

Market Research Future projects the global insulin syringes market will grow from $1.99 billion in 2026 to $3.00 billion by 2035, driven by rising diabetes cases, safety-engineered product mandates and lower-cost delivery versus pens and pumps. The forecast points to faster growth in home care, Asia-Pacific demand and connected syringe technology over the next decade.

Why it matters: - The insulin syringes market is tied to long-term diabetes treatment demand, making it less dependent on discretionary healthcare spending. - Rising diabetes prevalence, safety mandates and cost-sensitive adoption in emerging markets are expanding both volume and value. - The market is projected to reach $3.00 billion by 2035, up from $1.99 billion in 2026.

What happened: - Market Research Future said the global insulin syringes market was valued at $1.90 billion in 2025. - The firm forecast 4.70% compound annual growth from 2026 to 2035. - The report said the market will grow from $1.99 billion in 2026 to $3.00 billion by 2035. - The source included a free sample request, customization request and full report.

The details: - The International Diabetes Federation projected 643 million adults living with diabetes by 2030. - The IDF Diabetes Atlas 10th Edition said 537 million adults had diabetes in 2021 and projected 783 million by 2045. - The report said newly diagnosed insulin-dependent patients typically enter a multi-decade consumable cycle. - Intensive insulin regimens can require 3 to 4 syringes daily. - Type 2 diabetes makes up more than 90% of global diabetes cases. - Type 1 diabetes is the fastest-growing disease segment in the report, at 5.50% CAGR. - The report said Type 1 patients often inject 4 to 6 times daily. - Safety-engineered syringes are benefiting from OSHA Bloodborne Pathogens Standard compliance in the U.S. - The EU Sharps Directive is driving similar adoption across member states. - Safety-engineered and low dead-space syringes can raise average selling prices by 30% to 50% per unit, according to the report. - Low dead-space syringes retain less than 2 units of residual insulin per injection, versus more than 5 units in conventional designs. - The report said that can save 10% to 15% of insulin annually per patient. - A 100-count box of U-100 insulin syringes retails below $15 in most U.S. pharmacies. - Monthly pen needle supplies cost $40 to $75, while insulin pump consumables exceed $300 per month. - Patent expirations on major insulin analogs between 2024 and 2028 are expected to bring 15 to 20 biosimilar insulin products to India, Brazil and Southeast Asia.

Between the lines: - The market appears to be shifting from a low-margin commodity category toward a more premium mix as safety and compliance requirements spread. - The report’s strongest growth logic comes from structural diabetes demand, not device replacement cycles. - Emerging markets still favor syringes because the cost gap with pens and pumps remains wide. - Connected syringe features and sustainability requirements may add a second layer of product differentiation by the early 2030s.

What's next: - The report said 0.5 mL syringes will remain the dominant size segment, with 47.3% revenue share in 2025. - The 1.0 mL syringe segment is expected to grow fastest at 5.50% CAGR through 2035. - Hospitals and clinics held the largest end-user share at 51.0% in 2025. - Home-care settings are forecast to grow fastest at 5.60% CAGR as self-administration expands. - North America held about 43% of the market in 2025, led by the U.S. - Asia-Pacific is projected to be the fastest-growing region at 5.55% CAGR. - The report said connected syringe caps that log dose and injection time are already in pilot programs at three major U.S. health systems. - The report also said European and Asian extended producer responsibility rules will push manufacturers toward recyclable and lighter materials by 2030.

The bottom line: - Insulin syringes remain a basic diabetes tool, but the market is moving toward safer, smarter and more regulated products as global diabetes treatment demand keeps rising.